MARKET

AXLA

AXLA

Axcella Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.29
-0.19
-3.47%
Pre Market 06:23 07/06 EDT
OPEN
5.45
PREV CLOSE
5.48
HIGH
5.51
LOW
5.25
VOLUME
118.29K
TURNOVER
--
52 WEEK HIGH
9.87
52 WEEK LOW
2.250
MARKET CAP
189.59M
P/E (TTM)
-1.7491
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AXLA stock price target is 18.00 with a high estimate of 28.00 and a low estimate of 8.00.

EPS

AXLA News

More
Axcella Health (AXLA) Jumps: Stock Rises 5.9%
Zacks · 4d ago
Axcella Health Inc. (AXLA) Moves to Strong Buy: Rationale Behind the Upgrade
Axcella Health Inc. (AXLA) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 06/24 16:00
Has Axcella Health (AXLA) Outpaced Other Medical Stocks This Year?
Is (AXLA) Outperforming Other Medical Stocks This Year?
Zacks · 06/24 15:30
Exelixis (EXEL) in Focus: Stock Moves 7.6% Higher
Zacks · 06/23 04:02
Alnylam???s Share Price Rises YTD on Pipeline Developments
Zacks · 06/17 14:50
Axcella Announces Patent Issuances Covering AXA1665
Benzinga · 06/17 12:15
Axcella Announces Patent Issuances Covering AXA1665
Both of Axcella’s lead product candidates, AXA1665 and AXA1125, now covered under U.S. patents for composition of matter and methods of use.
Business Wire · 06/17 12:00
bluebird Reports New Data on Betibeglogene Autotemcel for TDT
Zacks · 06/15 15:59

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About AXLA

Axcella Health Inc. is a biotechnology company. The Company focuses on research and development of multifactorial interventions to support health and address dysregulated metabolism across a spectrum of consumers. It designs and develops endogenous metabolic modulators. Its AXA Development Platform produces a pipeline of AXA candidates with programs in liver, muscle and blood. The Company’s wholly owned pipeline comprises five programs focused on the metabolic functions of the liver, muscle and blood. It offers AXA1665 for use in treating Hepatic Encephalopathy; AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease; AXA2678 for use in treating immobilization-induced acute muscle atrophy; and AXA4010 to target multiple biological pathways.
More

Webull offers kinds of Axcella Health Inc stock information, including NASDAQ:AXLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXLA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXLA stock methods without spending real money on the virtual paper trading platform.